Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) [Phase 1]
A Phase 1 clinical trial evaluating STX-0712 in patients with advanced hematologic malignancies is currently recruiting. The study includes …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer [Phase 2]
Phase 2 clinical trial evaluating FLAG-Ida chemotherapy followed by reduced-intensity total body irradiation and donor hematopoietic cell tr…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed [Phase 1, Phase 2]
Phase 1/2 study of guadecitabine plus atezolizumab in adults with advanced myelodysplastic syndrome or chronic myelomonocytic leukemia that …
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms [Phase 1]
Phase 1 safety, tolerability and preliminary efficacy study of NC525 in adults with advanced myeloid neoplasms has been terminated and resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML [Phase 1]
Phase 1 dose-escalation trial evaluating LP-108 as monotherapy and in combination with azacitidine in adults with relapsed or refractory mye…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study evaluating the combination of venetoclax and azacitidine for relapsed or refrac…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [Phase 2]
A Phase 2 rollover study from Novartis continues Sabatolimab (MBG453) treatment for patients who completed a prior study, to assess continue…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies [Phase 1]
Hu8F4 is being studied in a Phase 1 trial for multiple advanced hematologic malignancies; the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML
This clinical trial update covers the efficacy and safety of combining hypomethylating agents with venetoclax versus hypomethylating agents …
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT [Phase 1]
Phase 1 trial evaluating a combination of CD25/Treg-depleted donor lymphocyte infusion with ipilimumab for relapse of myeloid diseases after…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) [Phase 1, Phase 2]
This Phase I/II clinical trial is evaluating Axatilimab, a CSF1R monoclonal antibody, in combination with ruxolitinib for myelofibrosis and …
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts [Phase 2]
A Phase II trial is evaluating a combination regimen of cladribine and low-dose cytarabine with venetoclax, alternating with azacitidine and…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation [Phase 2]
A Phase 2 dose-expansion study evaluating a low-dose post-transplant cyclophosphamide/tacrolimus/ruxolitinib regimen for graft-versus-host d…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN [Phase 1]
This Phase 1 trial update reports adding venetoclax to fludarabine and busulfan conditioning before transplant and to maintenance therapy fo…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes [Phase 2]
Phase 2 trial evaluating adding pomalidomide to the standard liposomal daunorubicin/cytarabine chemotherapy in newly diagnosed acute myeloid…
-
EMA approval · 2025-12-18EMA Authorised: Azacitidine Kabi (azacitidine) — Fresenius Kabi Deutschland GmbH
EMA authorised Azacitidine Kabi (azacitidine) from Fresenius Kabi Deutschland GmbH for use in the EU. The product is indicated for myelodysp…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) [Phase 3]
Phase 3 study evaluating MBG453 in combination with azacitidine in adults with intermediate/high/very high risk myelodysplastic syndromes (p…
-
EMA approval · 2025-12-12EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited
EU authorisation granted for Azacitidine Mylan for treatment of myelodysplastic syndromes and certain leukemias, expanding access to azaciti…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) [Phase 3]
A Phase 3 randomized trial evaluating IMM01 plus azacitidine versus placebo plus azacitidine in newly diagnosed chronic myelomonocytic leuke…
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies [Phase 1]
A Phase 1 study of Dual-Signaling Protein 107 (DSP107) in hematologic malignancies has been terminated, including studies in Acute Myeloid L…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating guadecitabine in combination with donor lymphocyte infusion for acute myeloid leukemia, chronic myelomonoc…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Personalized NK Cell Therapy in CBT [Phase 2]
A Phase 2 trial from MD Anderson is evaluating personalized NK cell therapy across several hematologic cancers. The study is currently recru…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse [Phase 1, Phase 2]
This clinical trial evaluates decitabine in combination with the FLAG-Ida chemotherapy regimen and total-body irradiation, followed by donor…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) [Phase 2]
Phase 2 study update for participants who previously took ASTX727 (oral decitabine/cedazuridine) that is currently enrolling by invitation.